Concerta (Methylphenidate) -To-Generic Switch Study
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to identify whether, after adjustment for confounders
via stratification on a propensity score and adjustment for calendar year, the combined
endpoint consisting of #1 to #4 (1. switching back to Concerta, 2. changing the use of
immediate release [IR] methylphenidate, 3. beginning a new attention deficit hyperactivity
disorder [ADHD] medication, or 4. stopping both Concerta and the long acting [LA]
methylphenidate {authorized generic [AG] methylphenidate or equivalent generic [EG]
methylphenidate} that was begun on the index date), differs between participants who switch
from branded Concerta to the EG formulations versus participants who switch from branded
Concerta to the AG formulation.